Choice A rationale

While it’s true that bulimia nervosa can have serious health consequences, telling the patient that they “should stop because they need to” may come across as dismissive of the patient’s struggle. It’s important to remember that bulimia nervosa is a complex mental health disorder that often requires professional treatment.

Choice B rationale

Asking the patient why they engage in their behavior might seem like a logical question, but it could potentially make the patient feel defensive or blamed for their condition. It’s important to approach the conversation with empathy and understanding.

Choice C rationale

While it’s important to validate the patient’s feelings and experiences, saying “I’m proud of you for recognizing that this behavior is not normal” might not be the most therapeutic response. This statement could potentially reinforce the idea that their behavior is “abnormal,” which could lead to feelings of shame or guilt.

Choice D rationale

Expressing empathy and understanding, as in “It seems like you are feeling helpless about this behavior,” can be a therapeutic response. This statement acknowledges the patient’s feelings and opens up the conversation for further exploration of their experiences and potential coping strategies.

Platelet count is not the primary diagnostic test used to monitor the therapy’s effect of warfarin. Platelets are involved in the clotting process, but warfarin specifically works by inhibiting the synthesis of vitamin K-dependent clotting factors, which does not directly involve platelets.

Choice B rationale

The white blood cell count (WBC) is not used to monitor the effect of warfarin therapy. WBC is typically used to monitor for infection or inflammation, not the coagulation status of a patient.

Choice C rationale

Prothrombin time (PT) is the correct answer. Warfarin therapy is monitored using the PT, which is reported as the International Normalized Ratio (INR). Warfarin inhibits the synthesis of vitamin K-dependent clotting factors, which include Factors II, VII, IX, and X, and Proteins C and S. The PT/INR is sensitive to changes in these factors. An elevated INR indicates a higher risk of bleeding, while a lower INR suggests a higher risk of clotting.

Choice D rationale

Activated partial thromboplastin time (aPTT) is not typically used to monitor warfarin therapy. The aPTT test evaluates the intrinsic and common pathways of coagulation, which includes factors XII, XI, IX, VIII, X, V, II (prothrombin), and I (fibrinogen). Warfarin affects the extrinsic pathway and common pathway, not the intrinsic pathway. Therefore, aPTT is not the best test to monitor the effects of warfarin.